Protara Therapeutics (NASDAQ:TARA) Insider Sells $118,865.48 in Stock

Protara Therapeutics, Inc. (NASDAQ:TARA) insider Jacqueline Zummo sold 22,598 shares of the firm’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $5.26, for a total transaction of $118,865.48. Following the completion of the transaction, the insider directly owned 95,961 shares in the company, valued at approximately $504,754.86. This represents a 19.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Protara Therapeutics Stock Performance

NASDAQ:TARA opened at $5.11 on Friday. The firm’s fifty day simple moving average is $6.03 and its 200 day simple moving average is $5.59. Protara Therapeutics, Inc. has a twelve month low of $2.77 and a twelve month high of $7.82. The firm has a market capitalization of $276.35 million, a price-to-earnings ratio of -3.87 and a beta of 1.50.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings results on Tuesday, March 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.03). On average, analysts predict that Protara Therapeutics, Inc. will post -3.32 earnings per share for the current year.

Analyst Ratings Changes

TARA has been the topic of several analyst reports. Piper Sandler assumed coverage on Protara Therapeutics in a report on Wednesday, January 7th. They set an “overweight” rating and a $24.00 target price on the stock. TD Cowen reaffirmed a “buy” rating on shares of Protara Therapeutics in a research report on Tuesday, March 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and set a $23.00 target price on shares of Protara Therapeutics in a research report on Tuesday, February 10th. Finally, JPMorgan Chase & Co. began coverage on shares of Protara Therapeutics in a research note on Wednesday, March 4th. They issued an “overweight” rating and a $27.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.40.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Persistent Asset Partners Ltd purchased a new position in Protara Therapeutics in the fourth quarter valued at about $57,000. AXQ Capital LP purchased a new stake in Protara Therapeutics during the 4th quarter worth approximately $58,000. The Manufacturers Life Insurance Company purchased a new stake in Protara Therapeutics during the 4th quarter worth approximately $59,000. Quadrature Capital Ltd acquired a new position in shares of Protara Therapeutics in the 2nd quarter valued at approximately $35,000. Finally, Empery Asset Management LP purchased a new position in shares of Protara Therapeutics during the 4th quarter valued at approximately $68,000. Institutional investors and hedge funds own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.